MedTrace Logo

Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients

NCT02606409 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-08-23

No results posted yet for this study

Summary

Dexmedetomidine, a central and peripheral α2-receptor agonist distinct from GABA receptor for benzodiazepines and propofol, has been approved by the US Food and Drug Administration only for use up to 24 h in mechanically ventilated patients. The investigators aim to compare dexmedetomidine with propofol for sedation \>24h in poly traumatized mechanically ventilated patients.

Conditions

Interventions

DRUG

Dexmedetomidine

Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.

DRUG

Propofol

Propofol sedation at a starting dose of 10-70 µg/kg/hour.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Hala S Abdel-Ghaffar, MD · Assisstant professor in Anesthesia and intensive care department, faculty of medicine, Assiut university, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02606409 on ClinicalTrials.gov